Sabra Health Care REIT, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sabra Health Care REIT, Inc. (SBRA) on August 5, 2025. The filing discloses the entry into a new material definitive agreement for an equity distribution program and the simultaneous termination of a prior agreement.
Key Financial Metrics and Transaction Details
- New ATM Program Cap: Up to $750.0 million in aggregate gross offering price for Common Stock.
- Compensation: Up to $11.25 million in aggregate compensation to sales agents; forward purchaser commissions capped at 1.5% of the volume-weighted average price.
- Proceeds Usage: Net proceeds are intended to repay indebtedness, fund future investments, or serve general corporate purposes.
- Outstanding Forward Agreements: $266.5 million in shares subject to forward sale agreements from the prior program remain outstanding.
- Unsold Prior Capacity: $109.3 million in authorized shares under the terminated 2023 program were not sold.
Material Changes Versus Prior Period
The Company terminated its previous equity distribution agreement (the "2023 ATM Program") dated February 23, 2023, which had a cap of $500.0 million. This was replaced by a new agreement with a higher aggregate gross offering price cap of $750.0 million. The new agreement expands the consortium of agents and forward purchasers to include additional financial institutions such as Barclays, BMO, BofA, Citigroup, and others.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to contribute net proceeds to its Operating Partnership. Settlement of forward sale agreements is expected to occur within one year of entry, either through physical delivery of shares, cash settlement, or net share settlement.
Risks and Contingencies:
- Settlement Risk: If the Company elects to cash settle a forward sale agreement, it may not receive proceeds and could owe cash to the Forward Purchaser.
- Dilution Risk: If the Company elects to net share settle, it may owe shares of Common Stock without receiving proceeds.
- Market Conditions: Sales are subject to market conditions and may be suspended or terminated at any time.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of the $750 million offering cap.
- Review the status and settlement terms of the $266.5 million in outstanding forward sale agreements from the prior program.
- Examine the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific termination rights and settlement mechanics.
- Confirm the Company's current debt levels to assess the priority of using proceeds for debt repayment.